diagnost tool
price close busi juli
commerci cologuard fda-
screen test detect cancer pre-cancer
polyp develop suit liquid biopsi test
momentum appear solid
reiter top pick rais pt
late june privileg host manag two day investor
meet upbeat lot ground cover bottom line
freight train look pois steam ahead forese
futur reiter top pick rais pt
still start-up dont often ascrib compani start-up
given penetr rate one product manag vision
momentum build madison energ new open lab expand
capac tests/year believ get start
home run far expect momentum acceler
manag indic three-year partnership home run
far rep particularli obgyn rep train jan arent
fulli ramp yet add lyrica went patent two week ago
good reason think best day work realiz yet
reorder build indic rep priorit target cg reorder
given small base work peopl screen
reorder base doubl screen base doubl
order indic reorder everi year
improv week well potenti believ convers epic
track done acceler reorder patient year ago
expand outsid madison sinc local progress
palmetto noridian explor plan build acquir lab palmetto
noridian state includ limit california refrain
specul lab would ideal target acquir insist lab
would need focu cancer diagnost mani
choic given expertis lab oper regulatori affair
reimburs sale market patient complianc view exact ideal
partner choic compani could includ thrive grail other
cologuard aetna bcb ca alreadi cover cg age nice start
submit age label approv fda april think fda label
expans could hit earli ye line target increment
patient sum cologuard american
cologuard expect show data cologuard expect
cg increas rev lower cog
liquid biopsi bat order liver esophag pancreat cancer lung
nodul still plan target launch one new test per year
threat competit faq relat freenom grail thrive
believ steep barrier entri includ time get uspstf
guidelin final new guidelin expect around difficulti get
medicar coverag difficulti achiev high level sensit stage
cancer detect stage stage patient
prospect trial compani data set hover smaller studi
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
momentum appear
solid intact reiter
top pick rais pt
late june privileg host cfo jeff elliott gari fring
head ir megan jone two day investor meet upbeat
meet lot ground cover bottom line exact
scienc freight train look pois steam ahead forese futur
reiter top pick carri
rais price target made chang estim
price target use multipl unchang
revenu estim billion discount back two year discount rate
later year plan roll forward publish revenu estim
still start-up dont often ascrib compani start-
up given penetr rate one product vision manag
momentum build madison wisconsin energ anew new open
state-of-the-art lab expand capac tests/year
believ get start long runway cologuard whole
new fleet assay launch like tune new intern assay
home run far expect momentum acceler
manag indic three-year partnership terrif
home run phenomen start earli work togeth recal pfizer
intern medicin sale rep began sell cologuard octob
announc deal august conduct train septemb
saw ideal partner sinc primari care channel key part
done co-promot sixth largest advertis
unit state given size scale ad rate
lower use pay dont believ rep even fulli ramp
yet particularli obgyn rep train januari investor
meet indic go partnership lightli indic
studi dozen partnership agre term
manag indic learn lesson first pharma partnership
partner rep need incentiv
paid ironwood rep variabl comp character level low
result pay rep minimum commiss product sold
rep second posit minimum commiss sold rep third
posit indic pfizer rep get along well
learn lot
addit also abl purchas advertis rate
meaning sinc sixth largest advertis unit state
rep also longer tenur year averag rep number
rep good tie larg health system physician offic
part larger health system difficulti penetr
indic rep hungri sell cologuard particularli
sinc hasnt launch new product drug seven year cologuard presid
mark stenhous observ cg first rx-order product drug dx test
hasnt seen diminish return disclos publicli paid
annual rate math equival hire
new salespeopl assum all-in annual rep comp
buy unchang target price juli
diagnost tool
expect add intern sale count come year
remain seen choos renew partnership end
year think decis key swing factor much
plan scale sale forc next year add number pfizer
drug go patent near term viagra experienc loss exclus decemb
lyrica lost exclus two week ago fewer blockbust
product rep bag believ good reason rep give
attent cologuard indic sale forc overlap
rep quit low
choic take meet call mani compani look
partner given expertis lab oper regulatori affair reimburs sale
market patient complianc logic view exact ideal partner
choic dozen cancer diagnost compani might even logic
channel grail thrive someday launch pan-canc test view
indic meet peopl process place didnt dream
year ago manag team deep sophist
strong connect mani key player manag indic recent
invest thrive seri round small invest thu
believ would wrong think make big bet thrive
gateway liquid biopsi said opinion could strong
commerci partner thrive natur think alway possibl could
acquir thrive want add pan-canc assay content area high unmet
screen need ovarian pancreat cancer name two separ
recent privileg meet thrive understand
exact invest thrive essenti allow access thrive
manag team least time thrive form recent complet
exact new gi sale forc manag expect complet hire
gastrointestin gi sale forc next quarter exact expect half gi
sale forc promot within plan hire outsid
compani primari reason employ gi sale forc defus linger
anti-cologuard sentiment gastroenterologist drive referr
primari care physician work near gastroenterologist manag
indic us-bas gastroenterologist base
alreadi order least one cologuard manag indic
launch sale forc target gastroenterologist right thing achiev
goal obtain market share colon cancer screen market today
manag indic crucial gastroenterologist know
fact cologuard educ manag indic
gastroenterologist becom less resist idea order cologuard
patient convers indic compani want
ensur gastroenterologist inform spread right inform
believ gastroenterologist becom import referr sourc primari
care physician compani want ensur gastroenterologist
posit impact primari care physician sentiment order behavior
pcp work live near gastroenterologist
cologuard reorder everi three year build epic convers
track remind launch cologuard nov/dec
recommend patient get screen everi three year mean
larg number cologuard cg patient test three year ago
elig reorder indic cologuard reorder improv
week well potenti still success rate
indic sale forc priorit target cg reorder given
buy unchang target price juli
diagnost tool
rel small base work cg base much larger
put number peopl screen reorder base
doubl screen base doubl
order indic reorder everi three year improv
week well potenti indic sale forc get
understand cologuard reorder big opportun indic
initi target patient directli discov wasnt enough thu
reach doctor drive patient reorder indic learn
optim doctor order right patient due three-year anniversari
said perform chang address lookup patient move
believ convers epic track done help acceler
reorder patient order year ago
exact busi build integr capabl privileg
host gari fring exact chief inform offic investor meet
manag reiter goal go live epic onto epic care
network epic care link new provid migrat veeva
use well top pharma compani veeva built top
salesforc indic integr complet sale rep go
field ipad today go clinic paper visual aid
veeva enabl leverag commerci cloud close loop market
epic perform instal bill reimburs indic epic
provid whole new set tool isnt use today exampl
physician alert patient due anoth test three year
test complet indic partner epic make compani
think broadli beyond colon cancer limit particular type
cancer epic headquart madison wi street
team collabor close easili togeth two phase
integr first go live date expect sometim
second phase enabl cg reorder simpl easi button
manag indic order still receiv fax machin
order receiv electron manag indic
doctor e-ord order roughli twice much physician order fax
manag also believ approxim american epic record
larg hospit use epic hospit use
gain lab footprint outsid madison wi local medicar
administr contractor quit progress palmetto noridian
time exact explor plan build acquir lab palmetto noridian
jurisdict base understand count state oper
va wv oh ky tn ga al mo ks ne ia mi addit territori cover
palmetto includ american samoa guam north mariana island palmetto
state largest concentr clia lab awar includ
ca az wa ut nc mi
base understand noridian state includ ct ny nj de md pa ri
vt nh washington dc noridian state largest share lab
awar includ ny nj
sens look state like ca az wa ut near subsidiari
sampl mind lake citi nc mi ny nj lab expans
remind use incorpor would afford strong east coast
presenc access deep talent lab market near plenti world
top univers similar argument made ca load lab
access deep talent mani world top univers particularli lab
buy unchang target price juli
diagnost tool
manag indic oper lab within palmetto noridian
jurisdict may enabl faster medicar coverag local coverag decis
lcd oppos seek nation coverag decis ncd requir
screen test refrain specul lab would ideal target
acquir insist lab would logic need focu cancer
diagnost mani choos remind hold
billion cash balanc sheet wouldnt surpris see
make move establish anoth lab presenc
threat competit manag indic view liquid
biopsi threat cologuard due biolog technolog reason
think certainli nois liquid biopsi space
possibl sourc competit futur develop
clearli nois sourc concern view manag assert
goal achiev market share us colon cancer screen market
today time split market share today gold standard
colonoscopi assert remain market
combin fit/fobt test blood liquid biopsi test
manag assert blood-bas test cumul achiev
share predic view blood test achiev high
degre early-stag cancer sensit due biolog barrier expect
fluid debat next sever quarter year compani reveal
believ biolog barrier use blood detect early-stag colon
cancer exact spent year mayo clinic accur detect colon
cancer earli stage blood abl achiev data
good cologuard blood manag assert find what
blood indic inner wall colon doesnt
blood suppli thu difficult detect earli stage cancer blood manag
indic blood muscl area colon part colon
enabl better detect stage cancer assert truli
compel screen test requir detect rang stage cancer
detect colon cancer sensit stage cancer
stage cancer indic compani shown abil detect
stage blood similar level true howev note
liquid biopsi compani remain earli stage case yet
lock assay enrol assay larg data set
steep barrier entri assert barrier entri player
like grail freenom thrive launch colon cancer screen
test includ get unit state prevent servic task forc uspstf
screen guidelin final new guidelin expect next wave
guidelin possibl get medicar coverag difficulti achiev
high level sensit stage cancer stage
stage high cost clinic trial work high cost next-gen
sequenc manag view liquid biopsi threat
early-stag sensit compar level specif low manag
believ blood-bas colon cancer test abl achiev high enough
sensit guardant achiev stage cancer specif
sensit stage cancer target specif earli data read-out
manag also assert competitor data read case
control studi remind investor case control studi
move larg prospect deep-c studi lost point sensit
point specif sensitivity/specif
sensitivity/specif relat high cost spent deep-c
buy unchang target price juli
diagnost tool
studi sever year ago believ similar invest today dollar
far high cost barrier compani like
hard time rais lot money addit
indic compani use next-gener sequenc
particularli like struggl offer test scale low
enough cost good cite cogs/test estim around
sequenc similar level disclos view sequencing-
base test lower sensit requir annual test interv obtain lower
reimburs somewher around cg around think
earli make judgment figur given competitor assay
havent lock yet report larg data set note cost
sequenc remain rel high rel pcr test though trust
point lower cost sequenc custom eventu
achiev genom actual play time-frame
uspstf endors liquid biopsi test lower recommend screen
age unit state prevent servic task forc uspstf start
next phase draft review colon cancer screen guidelin uspstf
volunt group physician typic meet everi year examin peer-
review data determin whether new chang need made exist
guidelin final uspstf guidelin prove major victori exact
evid rate today colorect cancer screen list rate
recommend includ exass cologuard test investor analyst
alik interest uspstf two reason first determin new
 liquid biopsi screen test includ final uspstf screen
guidelin second see uspstf follow american cancer societi ac
rel new recommend recommend colon cancer screen begin
topic includ new screen test next wave guidelin exact
indic compani like freenom thrive instanc
run deadlin theyv probabl alreadi miss assert
uspstf arbit commerci payor coverag screen test clock
start januari manag expect final recommend sometim
around march indic task forc look prospect
data set took total year month time
enrol first patient larg deep-c studi new england journal
medicin public manag assert compani even start
prospect studi get publish thu believ compani like freenom
guardant thrive miss next round final screen guidelin expect
sometim around dont believ hard fast date exact
believ liquid biopsi compani need wait anoth review
believ next review like occur sometim around time
exact expect screen ten million peopl consist market
share goal screen market note freenom guardant
thrive world could elect pursu acceler dual path program fda
submiss medicar review success would allow compani
launch fda-clear test get reimburs medicar critic popul
peopl thu view uspstf import primarili
commerci payor reimburs sinc rate test must cover
commerci payor accord afford act howev uspstf alon
prevent competit think thrive instanc could
success get medicar reimburs market assay ovarian
pancreat test indic particularli sinc screen paradigm
buy unchang target price juli
diagnost tool
today cancer furthermor uspstf well handl pan-
cancer multi-canc screen test remain seen given type test
respect whether uspstf updat screen age popul
manag indic guarante uspstf lower screen
age indic expect evid cutoff done sometim around
next month indic go offens negoti
commerci payor lower age even uspstf updat
screen age remind aetna alreadi cover cologuard average-risk
american begin age
cologuard manag reiter goal obtain updat label
fda begin market american age group obtain
label mark first set test order age group
physician order cologuard off-label age addit major health
plan like aetna cross shield california alreadi cover cg
plan member age submit packag fda april
subject respons though clock stop fda
think fda label expans could grant earli ye line
manag goal indic anoth larg
studi indic abl submit enough evid prove cg util
individu age believ cologuard order could mark upsid
our/street estim peg increment age cohort
us patient billion
cologuard expect publish data later remind exact
commun goal develop new next-gener version cologuard
refer cologuard run larg trial take fda
expect report earli data sometim compani plan
use almost new lower cost biomark purpos obtain lower
fals posit rate today look reduc
impli peg specif higher hope achiev similar
level sensit cologuard today sensit specif
respect manag assert pushback order cologuard
test perceiv lack reimburs even though elig
american cover co-pay cologuard rel high fals
posit rate manag indic expect cologuard increas base
revenu lower cog cologuard
believ need continu pay low-single-digit royalti anymor
reduc spoilag rate extend shelf life three day six day
result test get complet cologuard test must process
within hour test collect today exact recommend patient
collect specimen friday saturday extend shelf life
abl process test success also expect lower cog
cologuard vs cologuard essenti remak cologuard
less expens marker manag also expect captur
revenu retain patient reorder paradigm reduc fals
posit manag indic expect continu brand new test
cologuard given strong grow brand recognit manag indic
commerci launch fda-clear cologuard somewher around
three year away time meet indic compani
yet met fda manag assert npv cg
brand-new lab expand annual test capac test per year late june
announc open new state-of-the-art lab add test
buy unchang target price juli
diagnost tool
capac lab oper least expect ye addit
initi lab capac test total lab capac million test per year
indic time may abl anoth beyond get
meet manag indic screen goal impli
tests/year thu end essenti done build lab
capac age screen cohort least remind
american today up-to-d colon cancer screen age
cohort sinc cologuard launch compani screen million
peopl employ peopl job open new
build total squar feet includ lab warehous
new lab oper newli renov offic build hous
custom care employe build larg park garag cafeteria
addit product manufactur space
liver cancer surveil liquid biopsi develop program
top cancer manag re-affirmed liver cancer surveil liquid biopsi
test advanc launch liquid biopsi test compani
pipelin manag indic yet decid regulatori path fda
ldt though wouldnt rule ldt launch initi follow fda
submission/clear manag indic one gate factor
govern decis relat whether fda allow fda de-novo
approv without necess conduct prospect clinic trial fda allow
retrospect samples/cas control believ would like priorit
fda path fda requir larger prospect trial think like path would
ldt launch undetermin time expect hear
updat manag indic liver cancer
guidelin group consensus-bas group quantit strict
evidence-bas uspstf manag also indic pancreat test
earlier stage develop compani previous releas
promis data show util
addit takeaway manag meet
engag passion start top strong ever trickl
cfo jeff elliott indic chairman ceo kevin conroy
probabl engag he ever time compani
intern blood data consist recent commentari
near-term plan unveil blood-bas colon cancer test data ask
wont reveal data manag indic isnt good enough
yet though believ data superior data shown guardant
freenom cell max life name three
 far made tuck-in acquisit help round
technolog capabl primarili biomark
biomark formerli licens mdx health sampl mind
biomatrica primarili blood collect tube use liquid
biopsi test manag indic would contempl make larger
acquisit target fit focu area cancer
diagnost manag indic acquisit would need fit
neatli primari care gi sale forc disrupt sell
lt target intact reiter goal achiev
screen market achiev om timet
given achiev goal manag provid timet
achiev profit though indic profit far
manag commit right long term
buy unchang target price juli
diagnost tool
price manag indic health plan price incred
stabl compani commit disciplin price includ
health plan renew give commerci payor
price medicar rate
reimburs progress consist recent disclosur manag
